The earnings call presented a mix of strong performance in the bioprocessing and diagnostics segments, alongside challenges in life sciences and high-growth markets. The company's innovation and new product launches highlight a focus on long-term growth, while global trade tensions and market declines in China pose ongoing challenges.

Company Guidance -

Q3 2025

During Danaher Corporation's second quarter 2025 earnings call, the company provided several key metrics and guidance for the year. Danaher reported sales of $5.9 billion for the second quarter, with a core revenue growth of 1.5%. The gross profit margin stood at 59.3%, while the adjusted operating profit margin was 27.3%, flat year-over-year. Adjusted diluted net earnings per share increased by approximately 5% to $1.80. The company also generated $1.1 billion in free cash flow for the quarter, resulting in a year-to-date free cash flow to net income conversion ratio of 143%. Looking ahead, Danaher maintained its full-year core revenue growth guidance at approximately 3% and increased its full-year adjusted diluted net EPS guidance to a range of $7.70 to $7.80. For the third quarter, Danaher anticipates core revenue growth in the low single-digit percent range and an adjusted operating profit margin of approximately 25.5%. The company noted robust growth in its bioprocessing business, with a high single-digit growth outlook for the second half of 2025, and highlighted strong secular growth drivers and a resilient portfolio as key factors supporting these expectations.

Strong Bioprocessing Performance

Bioprocessing business showed strong growth with low double-digit growth in consumables and high single-digit growth in the biotechnology segment.

Free Cash Flow and Earnings Growth

Generated $1.1 billion of free cash flow in the quarter, with adjusted diluted net earnings per share up approximately 5% year-over-year.

New Product Launches and Innovations

Significant investments in new products like Syteva's protein A resins and XenoTOS 8600 mass spectrometry, enhancing long-term competitive positioning.

Resilience in Diagnostics

Diagnostics segment showed core revenue increase of 2%, with Cepheid's non-respiratory revenue growing double digits.

CFO Succession Plan

Announced CFO succession with Matt Gugino taking over, ensuring continuity and leadership strength.

Danaher (DHR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DHR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 28, 2025	2025 (Q3)	1.73 / -	1.71	―	―	―
Jul 22, 2025	2025 (Q2)	1.64 / 1.80	1.72	4.65% (+0.08)
Apr 22, 2025	2025 (Q1)	1.63 / 1.88	1.92	-2.08% (-0.04)
Jan 29, 2025	2024 (Q4)	2.16 / 2.14	2.09	2.39% (+0.05)
Oct 22, 2024	2024 (Q3)	1.57 / 1.71	2.02	-15.35% (-0.31)
Jul 23, 2024	2024 (Q2)	1.57 / 1.72	1.817	-5.34% (-0.10)
Apr 23, 2024	2024 (Q1)	1.72 / 1.92	2.092	-8.22% (-0.17)
Jan 30, 2024	2023 (Q4)	1.91 / 2.09	2.544	-17.85% (-0.45)
Oct 24, 2023	2023 (Q3)	1.81 / 2.02	2.269	-10.97% (-0.25)
Jul 25, 2023	2023 (Q2)	1.78 / 1.82	2.446	-25.72% (-0.63)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DHR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 22, 2025	$188.07	$189.91	+0.98%
Apr 22, 2025	$184.67	$191.76	+3.84%
Jan 29, 2025	$247.07	$223.03	-9.73%
Oct 22, 2024	$270.93	$260.16	-3.98%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.